Alcon shares surge 5.03% after-hours on Q3 earnings beat and reaffirmed 2025 sales guidance.

Alcon surged 5.03% in after-hours trading following its Q3 2025 earnings report, which exceeded expectations on core earnings per share and reaffirmed full-year guidance. The results, including a 5% revenue increase to $2.6 billion and strong performance in surgical equipment and ocular health, alleviated investor concerns amid ongoing challenges with its STAAR Surgical acquisition. The stock’s rise aligned with analysts’ commentary highlighting relief over the confirmed outlook, despite margin pressures from tariffs and competitive dynamics. Key drivers included improved surgical equipment sales, particularly the Unity VCS platform, and positive market reception to new product launches like PanOptix Pro. The reaffirmed guidance and EPS beat, coupled with optimism about long-term growth strategies, fueled the post-earnings rally.